Participants will be asked to join this study because they have Lennox-Gastaut Syndrome (LGS), a rare type of epilepsy that results in abnormal brain activity and seizures. It usually starts at an early age and causes seizures which may be associated with loss of consciousness and violent muscle shaking. The currently approved antiseizure medications (ASMs) are sometimes not sufficient to treat LGS.
If you meet all the requirements, you may enroll into this study. This study will be conducted at multiple study centers globally.
The study will test YKP509 (also called carisbamate), an investigational drug that is being studied when given along with anti-seizure medications (ASMs) for epilepsy. An investigational drug means the drug has not been approved for use by any regulatory agencies.